ReviewSchizophrenia research2011
Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.
Review in Schizophrenia research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacological interventions for prevention of weight gain in people with schizophrenia.The Cochrane database of systematic reviews · 2022Pooled it
- Exposure to cigarette smoke during prenatal period alters the brain energy metabolism of rats subjected to an animal model of schizophrenia.Metabolic brain disease · 2026Article
- Clinical implications of autistic features in the psychosis spectrum: a cross-sectional study using path analysis.BMC psychiatry · 2025Article
- Translation from Preclinical Research to Clinical Trials: Transdermal Drug Delivery for Neurodegenerative and Mental Disorders.Pharmaceutical research · 2024Review
- Clinical characterization and differentiation of B-SNIP psychosis Biotypes: Algorithmic Diagnostics for Efficient Prescription of Treatments (ADEPT)-1.Schizophrenia research · 2023Article
- A preliminary study examining terminology used by individuals with lived experience describing beliefs about being targeted or harmed by others.Psychiatry research · 2023Article
- Niacin Skin Flush Backs-From the Roots of the Test to Nowadays Hope.Journal of clinical medicine · 2023Review
- What's in the name "schizophrenia"? A clinical, research and lived experience perspective.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023Article
- Emerging epigenetic dynamics in gut-microglia brain axis: experimental and clinical implications for accelerated brain aging in schizophrenia.Frontiers in cellular neuroscience · 2023Review
- Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects.Journal of clinical medicine · 2022Article
- Comprehensive and integrative analyses identify TYW5 as a schizophrenia risk gene.BMC medicine · 2022Article
- Markers of muscarinic deficit for individualized treatment in schizophrenia.Frontiers in psychiatry · 2022Article
- Infra-Low Frequency Neurofeedback rapidly ameliorates schizophrenia symptoms: A case report of the first session.Frontiers in human neuroscience · 2022Article
- What a Clinician Should Know About the Neurobiology of Schizophrenia: A Historical Perspective to Current Understanding.Focus (American Psychiatric Publishing) · 2020Article
- Toward incorporating genetic risk scores into symptom networks of psychosis.Psychological medicine · 2020Observational
- Neuroimaging in Schizophrenia.Neuroimaging clinics of North America · 2020Review
- Models Predicting Psychosis in Patients With High Clinical Risk: A Systematic Review.Frontiers in psychiatry · 2020Review
- Bivariate causal mixture model quantifies polygenic overlap between complex traits beyond genetic correlation.Nature communications · 2019Article
- The debate about renaming schizophrenia: a new name would not resolve the stigma.Epidemiology and psychiatric sciences · 2019Article
- Renaming schizophrenia: 5 × 5.Epidemiology and psychiatric sciences · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
The current construct of schizophrenia as a unitary disease is far from satisfactory, and is in need of reconceptualization. The first five papers in our "facts" series reviewed what is known about schizophrenia to date, and a limited number of key facts appear to stand out. Schizophrenia is characterized by persistent cognitive deficits, positive and negative symptoms typically beginning in youth, substantive heritability, and brain structural, functional and neurochemical alterations including dopaminergic dysregulation. Several pathophysiological models have been proposed with differing interpretations of the illness, like the fabled six blind Indian men groping different parts of an elephant coming up with different conclusions. However, accumulating knowledge is integrating the several extant models of schizophrenia etiopathogenesis into unifying constructs; we discuss an example, involving a neurodevelopmental imbalance in excitatory/inhibitory neural systems leading to impaired neural plasticity. This imbalance, which may be proximal to clinical manifestations, could result from a variety of genetic, epigenetic and environmental causes, as well as pathophysiological processes such as inflammation and oxidative stress. Such efforts to "connect the dots" (and visualizing the elephant) are still limited by the substantial clinical, pathological, and etiological heterogeneity of schizophrenia and its blurred boundaries with several other psychiatric disorders leading to a "fuzzy cluster" of overlapping syndromes, thereby reducing the content, discriminant and predictive validity of a unitary construct of this illness. The way ahead involves several key directions: a) choosing valid phenotype definitions increasingly derived from translational neuroscience; b) addressing clinical heterogeneity by a cross-diagnostic dimensional and a staging approach to psychopathology; c) addressing pathophysiological heterogeneity by elucidating independent families of "extended" intermediate phenotypes and pathophysiological processes (e.g. altered excitatory/inhibitory, salience or executive circuitries, oxidative stress systems) that traverse structural, functional, neurochemical and molecular domains; d) resolving etiologic heterogeneity by mapping genomic and environmental factors and their interactions to syndromal and specific pathophysiological signatures; e) separating causal factors from consequences and compensatory phenomena; and f) formulating or reformulating hypotheses that can be refuted/tested, perhaps in the mouse or other experimental models. These steps will likely lead to the current entity of schizophrenia being usefully deconstructed and reconfigured into phenotypically overlapping, but etiopathologically unique and empirically testable component entities (similar to mental retardation, epilepsy or cancer syndromes). The mouse may be the way to rescue the trapped elephant!
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.